<SEC-DOCUMENT>0001140361-24-002149.txt : 20240112
<SEC-HEADER>0001140361-24-002149.hdr.sgml : 20240112
<ACCEPTANCE-DATETIME>20240112164920
ACCESSION NUMBER:		0001140361-24-002149
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20240112
DATE AS OF CHANGE:		20240112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276493
		FILM NUMBER:		24532607

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>ny20018157x1_s3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="ny20018157x1_s3_200-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 24pt; text-align: center;">As filed with the Securities and Exchange Commission on January&#160;12, 2024 </div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2pt; text-align: right;">Registration No. 333-&#8195;&#8195; </div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">Washington, D.C. 20549 </font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 4.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 7.5pt; text-align: center;">FORM S-3<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt;">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 </font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 7pt; text-align: center;">Eterna Therapeutics Inc. <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 10pt;">(Exact name of registrant as specified in its charter) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">31-1103425 </div></td></tr><tr><td style="width: 48.89%; text-align: center; vertical-align: top; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 48.89%; text-align: center; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; text-align: center;">Identification No.)</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 3pt; text-align: center;">1035 Cambridge Street, Suite 18A<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cambridge, MA 02141<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 582-1199<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">including area code, of registrant&#8217;s principal executive offices) </font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 5pt; text-align: center;">Sanjeev Luther<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">President and Chief Executive Officer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Eterna Therapeutics Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">1035 Cambridge Street, Suite 18A<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cambridge, MA 02141 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 1pt; text-align: center;">(212) 582-1199<font style="font-weight: normal;"> </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, </font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">including area code, of agent for service) </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-style: italic; margin-top: 3pt; text-align: center;">Copies to:<font style="font-style: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 3pt; text-align: center;">Cheryl Reicin, Esq. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jeffrey P. Schultz, Esq.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">919 Third Avenue<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, NY 10022<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 0pt; text-align: center;">(212) 935-3000 </div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Approximate date of commencement of proposed sale to the public: From time to time after this Registration Statement becomes effective.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If the only securities being registered on this Form&#160;are being offered pursuant to dividend or interest reinvestment plans, please check the following box: <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: &#x2612; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule&#160;462(e) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If this Form&#160;is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule&#160;413(b) under the Securities Act, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 31.11%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-accelerated filer &#x2612;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 31.11%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company &#x2612; </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.11%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.7pt; font-weight: bold; margin-top: 3pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.<font style="font-weight: normal;"> </font></div></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20018157x1_s3_201-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><div style="color: #FC0014; font-family: Arial, Helvetica, sans-serif; font-weight: bold; text-align: left; margin-bottom: 12pt;">The information in this prospectus is not complete and may be changed. Neither we nor the Selling Stockholders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</div> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 32.68%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 11pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PRELIMINARY PROSPECTUS</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 31.58%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 11pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SUBJECT TO COMPLETION</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 30.48%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 11pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">DATED JANUARY&#160;12, 2024</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 20.75pt; text-align: center;">Eterna Therapeutics Inc.<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 11pt;">Up to 18,233,359 Shares of Common Stock </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus relates to the offering and resale from time to time by the selling stockholders identified in this prospectus (the &#8220;Selling Stockholders&#8221;) of up to 18,233,359 shares of our common stock, $0.005 par value per share (&#8220;common stock&#8221;), composed of (i) up to 4,789,507 shares of common stock (the &#8220;Note&#160;Conversion Shares&#8221;) issuable upon the conversion of the Company&#8217;s 12% Senior Convertible Notes (the &#8220;Notes&#8221;) that were issued to Selling Stockholders in a private placement consummated in December&#160;2023 and January&#160;2024 (the&#160;&#8220;Private Placement&#8221;), (ii) up to 3,864,838 shares of common stock that may become issuable upon conversion of capitalized pay-in-kind interest that may accrue through the maturity date of the Notes (the &#8220;PIK Interest Conversion Shares&#8221; and together with the Note&#160;Conversion Shares, the &#8220;Conversion Shares&#8221;) and (iii)&#160;up to 9,579,014 shares of common stock (the &#8220;Warrant Shares&#8221;) issuable upon the exercise of warrants issued to Selling Stockholders in the Private Placement (the &#8220;Warrants&#8221;). The foregoing securities issued in the Private Placement were acquired by certain Selling Stockholders on December&#160;15, 2023 and by the remainder of the Selling Stockholders on January&#160;11, 2024 in a private placement pursuant to a purchase agreement among us and such Selling Stockholders, dated December&#160;14, 2023. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are registering the Conversion Shares and the Warrant Shares pursuant to the Selling Stockholders&#8217; registration rights contained in that certain Registration Rights Agreement, dated December&#160;14, 2023, by and among us and such Selling Stockholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders may offer, sell or distribute all or a portion of the shares of common stock registered hereby publicly or through private transactions at prevailing market prices or at negotiated pries. We provide more information about how the Selling Stockholders may sell their respective shares of our common stock in the section entitled &#8220;<font style="font-style: italic;">Plan of Distribution</font>.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We will pay certain fees and expenses in connection with the registration of the common stock offered hereby, and we will not receive any proceeds from the Selling Stockholders&#8217; sale of the shares of common stock offered hereby. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ERNA.&#8221; On January&#160;11, 2024, the closing price of our common stock was $1.76. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">INVESTING IN OUR SECURITIES INVOLVES RISKS THAT ARE DESCRIBED IN THE &#8220;RISK&#160;FACTORS&#8221; SECTION BEGINNING ON PAGE <a href="#tRF">4</a> OF THIS PROSPECTUS.<font style="font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 206.5pt; text-align: center;">The date of this prospectus is &#8195;&#8195;, 2024.</div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_202-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tABT">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tABT"><font style="padding-left: 4.44pt;">ii</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPRO">PROSPECTUS SUMMARY<font style="padding-left: 2.84pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPRO"><font style="padding-left: 5pt;">1</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTHE">THE OFFERING<font style="padding-left: 2.85pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTHE"><font style="padding-left: 5pt;">3</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">4</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.2pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 5pt;">5</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUOP"><font style="padding-left: 5pt;">6</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.11pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS"><font style="padding-left: 5pt;">7</font> </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSS">SELLING STOCKHOLDERS<font style="padding-left: 0.82pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSS">10 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOD">13 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">15 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEX">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEX">15 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">INCORPORATION BY REFERENCE<font style="padding-left: 1.57pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIBR">16 </a></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 2.14%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">17</a></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should rely only on the information contained in this prospectus. No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date.<font style="font-weight: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_203-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tABT"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), using a &#8220;shelf&#8221; registration process. Under this prospectus, the Selling Stockholders may, from time to time, sell shares of our common stock described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities offered by the Selling Stockholders. Any prospectus supplement may also add, update or change information contained in this prospectus. Any statement that we make in this prospectus will be modified or superseded by any inconsistent statement made by us in a prospectus supplement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The registration statement we filed with the SEC includes exhibits that provide more detail of the matters discussed in this prospectus. This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read this prospectus and the related exhibits filed with the SEC and any prospectus supplement, together with additional information described under the headings &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation by Reference&#8221; before making your investment decision. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should rely only on the information incorporated by reference or provided in this prospectus, any prospectus supplement and the registration statement. Neither we nor any Selling Stockholder has authorized anyone else to provide you with different or additional information other than that contained in or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Offers to sell, and solicitations of offers to buy, our common stock are being made only in jurisdictions where offers and sales are permitted. You should assume that the information in this prospectus and any prospectus supplement, or incorporated by reference, is accurate only as of the respective dates of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20018157x1_s3_204-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPRO"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus summary highlights selected information appearing elsewhere in this prospectus and in documents we file with the SEC that are incorporated by reference in this prospectus. Because it is a summary, it may not contain all of the information that may be important to you. To understand this offering fully, you should read this entire prospectus carefully, including the information incorporated by reference herein, the information set forth under the heading &#8220;Risk Factors&#8221; and our financial statements and the related notes thereto incorporated by reference in this prospectus<font style="font-style: normal;">. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Unless the context otherwise requires, all references in this prospectus to the &#8220;Company,&#8221; &#8220;Eterna,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Eterna Therapeutics Inc.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Overview </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines. We have in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSliceTM and UltraSliceTM gene-editing proteins, and the ToRNAdoTM mRNA delivery system, which we collectively refer to as our &#8220;mRNA technology platform.&#8221; We plan to develop and advance a pipeline of therapeutic products, both internally and through strategic partnerships, with the near-term focus on deploying our mRNA technology platform through strategic partnerships. We license our mRNA technology platform from Factor Bioscience Limited under an exclusive license agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Through strategic partnerships, we expect that our mRNA technology platform will be used for preclinical and eventual clinical development of product candidates for a variety of clinical indications. We expect that the initial product candidates developed by our strategic partners utilizing our mRNA technology platform will include hypoimmune induced pluripotent stem cell-derived product candidates for the treatment of neurological indications and iPSC-derived immune-modulating cells for indications such as acute myeloid leukemia and solid tumors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 and our subsequent reports filed pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), provide additional information about our business, operations and financial condition. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Private Placement of Notes and Warrants </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On December&#160;14, 2023, we entered into a Securities Purchase Agreement with the Selling Stockholders providing for the private placement (the &#8220;Private Placement&#8221;) to such Selling Stockholders of (i) $9,193,000 in aggregate principal amount of the Company&#8217;s 12.0% Senior Convertible Promissory Notes due five years from issuance (the &#8220;Notes&#8221;) and (ii) warrants, each exercisable to purchase one share of common stock at an exercise price of $1.43 per share (the &#8220;Warrants&#8221;). The initial closing of the Private Placement occurred on December&#160;15, 2023, and the second closing occurred on January&#160;11, 2024. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Notes (including any PIK Interest, as defined below, accruing thereon) may be converted to shares of common stock at an initial conversion price of $1.9194, subject to customary adjustments for stock splits, stock dividends and recapitalizations, as described in the Notes. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Notes are the general senior unsecured obligations of the Company and rank equal in right of payment with all of the Company&#8217;s existing and future unsubordinated indebtedness. The Notes bear interest at 12.0% per annum, payable quarterly in arrears on January&#160;15, April&#160;15, July 15 and October&#160;15 of each year, commencing on January&#160;15, 2024. At its election, the Company may pay interest either in cash or in-kind by increasing the outstanding principal amount of the Notes (such interest paid pursuant to an increase in outstanding principal, &#8220;PIK Interest&#8221;). The Notes mature five years from issuance, unless earlier converted or repurchased. The Company may not redeem the Notes at its option prior to maturity. The Notes purchased by the Selling Stockholders contain conversion limitations, providing that no conversion may be made if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99%, 9.99% or 19.99% immediately after conversion thereof, subject to certain increases not in excess of either 9.99% or 19.99% at the option of such holder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company issued an aggregate of 9,579,014 Warrants, each of which has an exercise price of $1.43 per share of common stock. The Warrants are immediately exercisable, expire five years from the date of issuance and are subject to customary adjustments. The Warrants purchased by the Selling Stockholders contain a provision pursuant </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20018157x1_s3_204-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">to which such Warrant may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99%, 9.99% or 19.99% immediately after exercise thereof, subject to certain increases not in excess of either 9.99% or 19.99% at the option of such holder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In connection with the Private Placement, we entered into a Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) on December&#160;14, 2023 with the Selling Stockholders, pursuant to which we agreed to register the Conversion Shares and the Warrant Shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus covers the sale or other disposition by the Selling Stockholders of up to the total number of shares of our common stock that issuable upon the conversion of the Notes issued to such Selling, plus the total number of shares of our common stock issuable upon exercise of the Warrants issued to such Selling Stockholders, without giving effect to the beneficial ownership limitations described above; therefore, the number of shares of common stock beneficially owned by certain of the Selling Stockholders may be less than the number of shares of common stock registered for resale by such Selling Stockholders hereunder. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Eterna Therapeutics Inc. was incorporated under the laws of Delaware in 1984. We changed our name from our initial name Alroy Industries, Inc. to NTN Communications, Inc. in 1985, to NTN Buzztime, Inc. in 2005, to Brooklyn ImmunoTherapeutics, Inc. in 2021 and to Eterna Therapeutics Inc. on December&#160;20, 2022. Our principal executive office is located at 1035 Cambridge Street, Suite 18A, Cambridge, Massachusetts 02141, and our telephone number is (212) 582-1199. We maintain a website at www.eternatx.com. Information contained on or accessible through our website is not incorporated by reference and does not form a part of this prospectus or the registration statement of which this prospectus forms a part. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="ny20018157x1_s3_204-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTHE"><!--Anchor--></a>THE OFFERING </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Resale of Common Stock </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 192pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common Stock Offered by the Selling Stockholders <font style="padding-left: 3.96pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 216pt; text-align: left;">Up to 18,233,359 shares. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 192pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of Proceeds <font style="padding-left: 5.54pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 216pt; text-align: justify;">We will not receive any of the proceeds from the sale of the shares of common stock by the Selling Stockholders. However, we may receive the proceeds from any exercise of any of the Warrants if the holders do not exercise the Warrants on a cashless basis. See the section of this prospectus titled &#8220;Use of Proceeds.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 192pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Market for Our Shares of Common Stock <font style="padding-left: 3.13pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 216pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ERNA.&#8221; </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 192pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk Factors <font style="padding-left: 3.08pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 216pt; text-align: justify;">Any investment in the securities offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_205-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">An investment in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in Item&#160;1A of Part&#160;I of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, including our audited consolidated financial statements and the related notes, and our subsequent reports filed pursuant to the Exchange Act, which are incorporated by reference in this prospectus before you decide whether to purchase our common stock. If any of such risks actually occur, our business, financial condition, results of operations, cash flow and prospects could be materially and adversely affected. As a result, the trading price of our common stock could decline and you could lose all or part of your investment in our common stock. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_206-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFLS"><!--Anchor--></a>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus contains forward-looking statements. Certain statements in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our dependence on in-licensed intellectual property; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our ability to enter into and sustain strategic partnerships with respect to the potential licensing of our intellectual property; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents and investments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our intellectual property position and strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments relating to our competitors and our industry; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impact of government laws and regulations; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to continue as a going concern. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The forward-looking statements contained in this prospectus are based on current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties, some of which are beyond our control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section entitled &#8220;Risk Factors&#8221; and in our periodic filings with the SEC. Our SEC filings are available publicly on the SEC website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Accordingly, forward-looking statements in this prospectus should not be relied upon as representing our views as of any subsequent date, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_207-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We will not receive any of the proceeds from the sale of any common stock offered by this prospectus, but we will bear all fees and expenses incident to our obligation to register the shares of common stock being offered for resale hereunder by the Selling Stockholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We may receive proceeds from the exercise of the Warrants and issuance of the Warrant Shares. If all of the&#160;Warrants were exercised for cash in full, the proceeds would be approximately $13.7&#160;million. We intend to use the net proceeds of such warrant exercises, if any, for research and development, general and administrative expenses, and for working capital purposes. We can make no assurances that any of the Warrants will be exercised, or if exercised, that they will be exercised for cash. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_208-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDCS"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following summary of the material terms of our capital stock is not intended to be a complete summary of the rights and preferences of such securities. We urge you to read our restated certificate of incorporation, including the amendments thereto, which we refer to as our certificate of incorporation, and our amended and restated bylaws, which we refer to our bylaws, in its entirety for a complete description of the rights and preferences of our capital&#160;stock.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Authorized and Outstanding Stock </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.005 per share, and 1,000,000 shares of preferred stock, par value $0.005 per share (the &#8220;preferred stock&#8221;). A total of 156,112 shares of preferred stock have been designated as Series&#160;A Convertible Preferred Stock (the &#8220;Series&#160;A Preferred Shares&#8221;). As of January&#160;11, 2024, 5,410,331 shares of common stock were outstanding and 156,112 Series&#160;A Preferred Shares were outstanding. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Voting Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Votes may be cast in person or by proxy. Stockholders do not have cumulative voting rights with respect to election of directors. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Dividends </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The holders of Series&#160;A Preferred Shares are entitled to receive cumulative dividends of $0.10 per share per annum, payable semiannually in equal installments of $0.05 per share on June&#160;1 and December&#160;1 of each year. After the requirements with respect to the preferential dividends of the preferred stock have been met, holders of common&#160;stock are entitled to receive proportionately any dividends as may be declared and paid on common stock from funds lawfully available therefor as and when determined by the board of directors, subject to any preferential dividend rights of outstanding preferred stock. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Liquidation and Dissolution </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Holders of common stock have no preemptive, subscription, redemption or conversion rights and there are no sinking fund provisions with respect to our common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock. All of the shares of the common stock currently issued and outstanding are fully-paid and nonassessable. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Provisions of Our Certificate of Incorporation and Bylaws and Delaware General Corporation Law may have Anti-Takeover Effects </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our certificate of incorporation and bylaws and the Delaware General Corporation Law (&#8220;DGCL&#8221;) contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and are designed in part to encourage persons seeking to acquire control of us to first negotiate with the board of directors. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Number of Directors; Vacancies </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our certificate of incorporation provides that the number of directors is established by the board of directors, which may delay the ability of stockholders to change the composition of a majority of the board. The board has the exclusive right to elect a director to fill any vacancy or newly created directorship. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_208-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Removal of Directors </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">A director may be removed only by the affirmative vote of the holders of at least 80% of the voting power of all shares entitled to vote generally in the election of directors, voting together as a single class. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Stockholder Action by Written Consent; Special Meetings </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our certificate of incorporation and bylaws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by the board of directors. These provisions may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Advance Notice Requirements for Stockholder Proposals </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting may consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Delaware Business Combination Statute </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a Delaware corporation subject to Section&#160;203 of the DGCL. Under Section&#160;203, certain &#8220;business combinations&#8221; between a Delaware corporation whose stock is listed on a national securities exchange or held of record by more than 2,000 stockholders and an &#8220;interested stockholder&#8221; are prohibited for a three-year period following the date that such stockholder became an interested stockholder, unless: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the corporation has elected in its certificate of incorporation not to be governed by Section&#160;203; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the business combination or the transaction which resulted in the stockholder becoming an interested stockholder was approved by the board of directors of the corporation before the date of the business combination or the date such stockholder became an interested stockholder, as applicable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">upon consummation of the transaction that made such stockholder an interested stockholder, the interested stockholder owned at least 85% of the &#8220;voting stock&#8221; (as defined in Section&#160;203) of the corporation outstanding at the commencement of the transaction excluding voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender stock held by the plan in a tender or exchange offer; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the business combination is approved by the board of directors and by the stockholders (acting at a meeting and not by written consent) by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not &#8220;owned&#8221; (as defined in Section&#160;203) by the interested stockholder. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The three-year prohibition also does not apply to some business combinations proposed by an interested stockholder following the announcement or notification of an extraordinary transaction involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the corporation&#8217;s directors. The term &#8220;business combination&#8221; is defined generally to include mergers or consolidations between a Delaware corporation and an interested stockholder, transactions with an interested stockholder involving the assets or stock of the corporation or its majority-owned subsidiaries and transactions which increase an interested stockholder&#8217;s percentage ownership of stock, or other transaction resulting in a financial benefit to the interested stockholder. The term &#8220;interested stockholder&#8221; is defined generally as those stockholders who become beneficial owners of 15% or more of a Delaware corporation&#8217;s voting stock, together with the affiliates or associates of that stockholder. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Certificate of Incorporation or Bylaws </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any provision of our certificate of incorporation may be amended, altered, changed or repealed in any manner prescribed by law; provided, that (a) the affirmative vote of the holders of at least 80% of the voting power of all </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_208-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">shares entitled to vote generally in the election of directors, voting together as a single class, is required to alter, amend, or repeal, or adopt any provision inconsistent with Article&#160;X of the certificate of incorporation, which contains the prohibition on stockholder action by written consent and the requirement that special meetings be called only by the board of directors, and (b) Article&#160;XI of the certificate of incorporation, provides that, subject to certain exceptions, no purchase by or from any Controlling Person (as defined below) of shares of our stock owned by such Controlling Person shall be made at a price exceeding the average price paid by such Controlling Person for all shares of our stock acquired by such Controlling Person during the two-year period preceding the date of such proposed purchase unless such purchase is approved by the affirmative vote of not less than a majority of the voting power of the shares of our stock entitled to vote held by Disinterested Stockholders (as defined below), may not be amended without the affirmative vote of not less than a majority of the our stock entitled to vote thereon, provided that if, at the time of such vote, there shall be one or more Controlling Persons, such affirmative vote shall include the affirmative vote in favor of such amendment of not less than a majority of the voting power of the shares of our stock entitled to vote thereon held by Disinterested Stockholders. &#8220;Controlling Person&#8221; means any individual, corporation, partnership, trust, association or other organization or entity (including any group formed for the purpose of acquiring, voting or holding our securities) which either directly, or indirectly through one or more intermediaries, owns, beneficially or of record, or controls by agreement, voting trust or otherwise, at least 10% of the voting power of stock, and such term also includes any corporation, partnership, trust, association or other organization or entity in which one or more Controlling Persons have the power, through the ownership of voting securities, by contract, or otherwise, to influence significantly any of the management, activities or policies of such corporation, partnership, trust, association, other organization or entity. &#8220;Disinterested Stockholders&#8221; means those holders of stock entitled to vote on any matter, none of which is a Controlling Person. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board may, by majority vote, amend or repeal our bylaws and may adopt new bylaws. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our stockholders may not adopt, amend, or repeal our bylaws or adopt new bylaws except by the vote or written consent of at least 66-2/3% of the voting power of our company. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Exclusive Forum Selection </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the a state court located in the State of Delaware (or if no state court has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to our company or stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the DGCL or our certificate of incorporation or amended and restated bylaws, or (d) any action asserting a claim against us governed by the internal affairs doctrine. Although our bylaws contain the choice of forum provision described above, it is possible that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Authorized but Unissued Shares </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing requirements of The Nasdaq Capital Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing on the Nasdaq Capital Market </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ERNA.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The transfer agent and registrar for the common stock is Computershare Trust Company, N.A. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_209-stockholders_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSS"><!--Anchor--></a>SELLING STOCKHOLDERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The shares of common stock being offered by the Selling Stockholders are the Conversion Shares and the Warrant Shares. For additional information regarding the issuance of the foregoing shares of common stock, the Warrants and the Notes, see &#8220;Prospectus Summary &#8211; Private Placement of Notes and Warrants&#8221; located elsewhere in this prospectus. We are registering the shares of common stock in order to permit the Selling Stockholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock offered hereby, the Warrants and the Notes, as applicable, and as otherwise disclosed in the footnotes to the table immediately below, none of the Selling Stockholders has had any material relationship with us within the past three years. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the Selling Stockholders. The second column (&#8220;Number of Shares of Common Stock Beneficially Owned Prior to Offering&#8221;) lists the number of shares of common stock beneficially owned by each Selling Stockholder. The beneficial ownership of our common stock is based on 5,410,331 shares of our common stock outstanding as of January&#160;11, 2024. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including derivative securities, such as options and warrants, that are currently exercisable or exercisable within 60 days. In computing the number of shares beneficially owned by a particular person or entity and the percentage ownership of that person or entity in the table below, all shares subject to options, Notes and Warrants held by such person or entity were deemed outstanding if such securities are currently exercisable or become exercisable within 60 days following of January&#160;11, 2024. These shares were not deemed outstanding, however, for the purpose of computing the percentage ownership of any other person or entity. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The third column (&#8220;Maximum Number of Shares of Common Stock to be Sold Pursuant to this Prospectus&#8221;) lists the shares of common stock being offered by this prospectus by the Selling Stockholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In accordance with the terms of the Registration Rights Agreement, this prospectus covers the resale of the sum of (i) the maximum number of shares of common stock issuable upon exercise of the Warrants, determined as if the outstanding Warrants were exercised in full as of the trading day immediately preceding the date the registration statement, of which this prospectus forms a part, was initially filed with the SEC, without regard to any limitations on the exercise of the Warrants, as described below, (ii) the maximum number of shares of common stock issuable upon conversion of the Notes, determined as if the outstanding Notes were converted in full as of the trading day immediately preceding the date the registration statement, of which this prospectus forms a part, was initially filed with the SEC, without regard to any limitations on the conversion of the Notes, as described above, and (iii) the maximum number of PIK Interest Conversion Shares issuable, assuming that the Company pays all interest on the Notes as PIK Interest through the maturity date of the Notes. The fourth column (&#8220;Number of Shares of Common Stock Owned After Offering&#8221;) presents the number of shares of common stock owned after this offering and assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the terms of the Notes, the Selling Stockholders may not convert the Notes to the extent such conversion would result in such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%, 9.99% or 19.99%, as applicable, of our then outstanding common stock following such conversion, excluding for purposes of such determination shares of common stock issuable upon conversion of such Notes which have not been converted. The number of shares in the third column (presenting the maximum number of shares of common stock to be sold pursuant to this prospectus) does not reflect this limitation, but the number of shares in all other columns reflect this limitation. The Selling Stockholders may sell all, some or none of their respective shares in this offering. See &#8220;Plan of Distribution.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under the terms of the Warrants, the Selling Stockholders may not exercise the Warrants to the extent such exercise would result in such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99%, 9.99% or 19.99%, as applicable, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the third column (presenting the maximum number of shares of common stock to be sold pursuant to this prospectus) does not reflect this limitation, but the number of shares in all other columns reflect this limitation. The Selling Stockholders may sell all, some or none of their respective shares in this offering. See &#8220;Plan of Distribution.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_209-stockholders_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Unless otherwise noted in the footnotes to the table immediately below, a Selling Stockholder may not exercise the Warrants or convert the Notes to the extent such exercise or conversion, as applicable, would result in such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% of our then outstanding common stock following such exercise or conversion. Given the foregoing limitations on exercise or conversion, the number of shares of common stock beneficially owned by a Selling Stockholders may be less than the number of shares of common stock registered for resale by such Selling Stockholder in accordance with the Company&#8217;s obligations under the Registration Rights Agreement. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Selling Stockholder</div></td><td class="gutter" rowspan="2" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 15.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prior to Offering</div></td><td class="gutter" rowspan="2" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 15.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Maximum<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock to be<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sold Pursuant to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">this Prospectus</div></td><td class="gutter" rowspan="2" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned After Offering </div></td></tr><tr class="header"><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.06%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amir Rozwadowski<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">157,679</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">99,165</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 12.5pt;">58,514</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">1.07</font> </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ashley Pettus<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">276,708</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">694,190</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">276,708</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">4.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beagle Limited<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">280,425</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">253,874</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">212,463</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">3.83% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beaumont Irrevocable Trust<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">280,425</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">495,840</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">280,425</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">4.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Charles Cherington<font style="padding-left: 0.63pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;">1,212,699<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">5,950,220</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">1,212,699<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">19.99% </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Daniel Lyons<font style="padding-left: 0.07pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 12.5pt;">54,195</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">29,747</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 12.5pt;">24,448</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David B. Thompson, Jr. <font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 12.5pt;">59,498</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">59,498</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Freebird Partners LP<font style="padding-left: 4.54pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;">1,283,570<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">1,983,406</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">1,283,570<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">19.99% </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">George Denny 2021 Trust<font style="padding-left: 3.03pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;">1,250,094<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">1,983,406</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;">1,250,091<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;">19.99% </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IAF, LLC<font style="padding-left: 4.47pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">576,918</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">1,190,042</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">576,918</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">9.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">John D. Halpern Revocable Trust<font style="padding-left: 2.59pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">550,283</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">1,983,406</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">550,283</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">9.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Milind Desai<font style="padding-left: 1.18pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">198,338</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">198,338</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pacific Premier Trust Custodian FBO David&#160;B. Thompson IRA<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 12.5pt;">39,664</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">39,664</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter F. Concilio<font style="padding-left: 0.59pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 12.5pt;">47,299</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">29,747</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 12.5pt;">17,552</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 22.5pt;">* </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase Capital LLC<font style="padding-left: 3.97pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">600,494</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;">1,983,362</div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">600,494</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">9.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Regolith Capital Investments LP<font style="padding-left: 1.2pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">284,154</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">991,703</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">284,154</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">4.99% </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stephen Older<font style="padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">150,587</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 12.5pt;">49,581</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">101,006</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">1.</font>84% </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tucker R. Halpern 2020 Trust<font style="padding-left: 1.26pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.87pt;">226,116</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">109,085</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.87pt;">117,031</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">2.12</font>% </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warren Street Legacy, LLC<font style="padding-left: 1.83pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.28pt; text-align: left;"><font style="padding-left: 7.5pt;">277,721</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.65pt; text-align: left;"><font style="padding-left: 7.5pt;">109,085</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.16pt; text-align: left;"><font style="padding-left: 7.5pt;">239,147</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.06%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.94pt; text-align: left;"><font style="padding-left: 5pt;">4.</font>33%</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents less than 1.0%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 34,964 shares of common stock issuable upon the exercise of warrants, 17,482 shares of common stock issuable upon the conversion of convertible notes and 6,068 shares of common stock issuable from maximum PIK interest. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 141,643 shares of common stock and 135,065 shares of common stock issuable upon the exercise of warrants. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 70,821 shares of common stock and 141,642 shares of common stock issuable upon the exercise of warrants. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 70,821 shares of common stock, 91,850 shares of common stock issuable upon the exercise of warrants 87,412 shares of common stock issuable upon the conversion of convertible notes and 30,342 shares of common stock issuable from maximum PIK interest for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 556,465 shares of common stock, 651,350 shares of common stock issuable upon the exercise of warrants, and 4,884 shares of common stock issuable upon the conversion of Series&#160;A Preferred Shares. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 19.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 4,290 shares of common stock, 15,490 shares of common stock issuable upon the exercise of warrants, 3,496 shares of common </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_209-stockholders_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: justify;">stock issuable upon the conversion of convertible notes and 1,213 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 272,583 shares of common stock, 657,724 shares of common stock issuable upon the exercise of warrants and 262,237 shares of common stock issuable upon the conversion of convertible notes and 91,026 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 19.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 406,989 shares of common stock, 367,200 shares of common stock issuable upon the exercise of warrants, 349,650 shares of common stock issuable upon the conversion of convertible notes, 121,368 shares of common stock issuable for maximum PIK interest for the convertible notes and 4,884 shares of common stock issuable upon the conversion of Series&#160;A Preferred Shares. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 19.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 212,464 shares of common stock, 246,700 shares of common stock issuable upon the exercise of warrants, 87,412 shares of common stock issuable upon the conversion of convertible notes and 30,342 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 9.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 452,284 shares of common stock and 98,000 shares of common stock issuable upon the exercise of warrants. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 9.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 10,488 shares of common stock issuable upon the exercise of warrants, 5,244 shares of common stock issuable upon the conversion of convertible notes and 1,820 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 250,844 shares of common stock issuable upon the exercise of warrants and 109,200 shares of common stock issuable upon the conversion of convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 9.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 244,754 shares of common stock issuable upon the exercise of warrants and 39,400 shares of common stock issuable for PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(14)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 14,164 shares of common stock, 63,292 shares of common stock issuable upon the exercise of warrants, 17,482 shares of common stock issuable upon the conversion of convertible notes and 6,068 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(15)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 69,930 shares of common stock issuable upon the exercise of warrants, 34,965 shares of common stock issuable upon the conversion of convertible notes and 12,136 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(16)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: justify;">Includes 122,116 shares of common stock, 69,930 shares of common stock issuable upon the exercise of warrants, 34,965 shares of common stock issuable upon the conversion of convertible notes and 12,136 shares of common stock issuable for maximum PIK shares for the convertible notes. The Notes and Warrants beneficially owned by this Selling Stockholder prohibit the conversion or exercise thereof if, after giving effect to such conversion or exercise, the Selling Stockholder, including any person whose beneficial ownership would be attributable to such Selling Stockholder, would exceed 4.99%. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_210-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Each Selling Stockholder and any of their respective pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the Nasdaq Capital Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling the securities offered hereby: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privately negotiated transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">settlement of short sales; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted pursuant to applicable law. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Selling Stockholders may also sell securities in accordance with Rule&#160;144, if available, or pursuant to any available exemption from registration under the Securities Act rather than under this prospectus. The Selling Stockholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, a Selling Stockholder that is an entity may elect to make an in-kind distribution of securities to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the distributees to use the prospectus to resell the securities acquired in the distribution. The Selling Stockholders also may transfer their respective securities in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling beneficial owners for purposes of this prospectus. Upon being notified by the Selling Stockholders that a donee, pledgee, transferee, other successor-in-interest intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name specifically such person as a Selling Stockholder. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule&#160;2121. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Subject to applicable law, in connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. Subject to applicable law, the Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_210-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any broker-dealers or agents that are involved in selling the securities offered hereby may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule&#160;144 without the requirement for the Company to be in compliance with the current public information under Rule&#160;144 under the Securities Act or any other rule of similar effect, (ii) all of the securities have been sold pursuant to this prospectus or Rule&#160;144 under the Securities Act or any other rule of similar effect or (iii) the securities offered by this prospectus have been disposed of by the Selling Stockholders (or the other holders of Registrable Securities (as defined in the Registration Rights Agreement)). The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not, subject to certain exceptions, simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule&#160;172 under the Securities Act). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ERNA.&#8221; The transfer agent and registrar for the common stock is Computershare Trust Company, N.A. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_211-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The validity of the securities offered by this prospectus has been passed upon for us by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, NY. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tEX"><!--Anchor--></a>EXPERTS </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The audited financial statements incorporated by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance upon the report of Grant Thornton LLP, independent registered public accountants, upon the authority of such firm as experts in accounting and auditing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The audited consolidated financial statements as of and for the year ended December&#160;31, 2021 of Eterna&#160;Therapeutics Inc. (formerly known as Brooklyn ImmunoTherapeutics, Inc.) incorporated by reference in this prospectus, have been so incorporated by reference in reliance upon the report of Marcum, LLP, independent registered public accounting firm, upon the authority of such firm as experts in accounting and auditing. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_212-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIBR"><!--Anchor--></a>INCORPORATION BY REFERENCE </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring to those documents. We hereby &#8220;incorporate by reference&#8221; the documents listed below, which means that we are disclosing important information to you by referring you to those documents. The Registration Statement, including the exhibits, can be read at the SEC website referred to below under &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221; The information that we file later with the SEC will automatically update and in some cases supersede this information. Specifically, we incorporate by reference the following documents or information filed with the SEC (other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036123012418/brhc10049677_10k.htm">March&#160;20, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Definitive Proxy Statement on Schedule 14A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123023073/ny20008400x2_def14a.htm">May&#160;5, 2023</a> in connection with our 2023 Meeting of Stockholders, and Definitive Additional Proxy Soliciting Materials on Schedule 14A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123023733/ny20008400x6_defa14a.htm">May&#160;10, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Quarterly Reports on Form&#160;10-Q filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036123024180/brhc20052635_10q.htm">May&#160;11, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036123039283/brhc20057085_10q.htm">August&#160;11, 2023</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036123052742/ef20012432_10q.htm">November&#160;13, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Current Reports on Form&#160;8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/748592/000114036123002909/brhc10046926_8k.htm">January&#160;4, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123001223/brhc10046500_8k.htm">January&#160;10, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123002909/brhc10046926_8k.htm">January&#160;26, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123008076/brhc10048628_form8k.htm">February&#160;22, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123017671/brhc10050812_8k.htm">April&#160;11, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123022489/brhc20052311_8k.htm">May&#160;2, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123023068/brhc20052521_8k.htm">May&#160;5, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123030499/brhc20054589_8k.htm">June&#160;20, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123034072/brhc20055728_8k.htm">July&#160;11, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123034310/brhc20055786_8k.htm">July&#160;13, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123034885/brhc20055909_8k.htm">July&#160;18, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123039073/brhc20057343_8k.htm">August&#160;10, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123042061/brhc20058268_8k.htm">August&#160;31, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123045249/ef20011289_8ka.htm">September&#160;26, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123047156/ef20011972_8k.htm">October&#160;5, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123050682/ef20013697_8k.htm">November&#160;1, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123053659/ef20014811_8k.htm">November&#160;16, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123057648/ef20016590_8k.htm">December&#160;14, 2023</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0000748592/000114036123058648/ef20016457_8k.htm">December&#160;20, 2023</a>; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the Company&#8217;s Registration Statement on Form&#160;8-A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121035202/brhc10030005_8a12b.htm">October&#160;22, 2021</a>, in which there is described the terms, rights and provisions applicable to the shares of the Company&#8217;s common stock, including any amendment or report filed for the purpose of updating such description, including the description of the common stock filed as Exhibit&#160;4.1 to the Company&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 filed on <a href="https://www.sec.gov/Archives/edgar/data/748592/000114036122014764/brhc10036185_ex4-1.htm">March&#160;20, 2023</a>. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (not including any information furnished under Item&#160;2.02, 7.01, or 9.01 of Form&#160;8-K or any other information that is identified as &#8220;furnished&#8221; rather than filed, which information is not incorporated by reference herein) after the initial filing date of the registration statement of which this prospectus is a part and prior to the effectiveness of the registration statement, as well as subsequent to the effectiveness of such registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the registration statement, of which this prospectus forms a part, and to be a part hereof from the date of filing of such documents. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of the registration statement, of which this prospectus forms a part, to the extent that a statement contained herein, or in any other subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of the registration statement, of which this prospectus forms a part. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request of that person, a copy of any and all of the information that has been incorporated by reference in this prospectus (excluding exhibits unless specifically incorporated by reference into those documents). Please direct requests to us at the following address: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Eterna Therapeutics Inc.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1035 Cambridge Street, Suite 18A<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Cambridge, MA 02141<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(212) 582-1199 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_212-incorp_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You may also access these filings on our website at www.eternatx.com. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus is part of a registration statement we filed with the SEC and does not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements, or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement, or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly, and current reports, proxy statements, and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our website address is www.eternatx.com. The information contained on, or accessible through, our website is not incorporated into this prospectus and does not form a part hereof. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="ny20018157x1_s3_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 22pt; font-weight: bold; margin-top: 254.75pt; text-align: center;">Eterna Therapeutics Inc. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Up to 18,233,359 Shares of Common Stock</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 54.5pt; text-align: center;">PROSPECTUS </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 96pt; text-align: center;">&#8195;&#8195;, 2024</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 206pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROSPECTUS </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;14.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Other Expenses of Issuance and Distribution. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following table sets forth the estimated expenses to be borne by the registrant in connection with the issuance and distribution of the securities being registered hereby. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Securities and Exchange Commission registration fee<font style="padding-left: 0.25pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">5,153.73 </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$33,000.00 </div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 4.11pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$25,000.00 </div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous fees and expenses<font style="padding-left: 4.13pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 5pt;">5,000.00 </font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.88%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$68,153.73</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;15.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section&#160;145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section&#160;145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Section&#160;145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section&#160;145 of the DGCL. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our certificate of incorporation provides that we will indemnify, in the manner and to the full extent permitted by law, any person (or the estate of any person) who was or is a party, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, and whether civil, criminal, administrative, investigative or otherwise, by reason of the fact that such person is or was our director, officer, employee or agent, or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Where required by law, the indemnification provided for shall be made only as authorized in the specific case upon a determination in the manner provided by law, that indemnification of the director, officer, employee or agent is proper under the circumstances. We may, to the full extent permitted by law, purchase and maintain insurance on behalf of any such person against any liability which may be asserted against him. To the full extent permitted by law, the indemnification provided shall include expenses (including attorneys&#8217; fees) in any action, suit or proceeding, or in connection with any appeal therein, judgments, fines and amounts paid in settlement, and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">in the manner provided by law any such expenses may be paid by us in advance of the final disposition of such action, suit or proceeding. The indemnification described herein does not limit our right to indemnify any other person for any such expense to the full extent permitted by law, nor is it exclusive of any other rights to which any person seeking indemnification from us may be entitled under any agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The board of directors has approved a form of indemnification agreement that has been executed by each of our directors and executive officers. In general, these agreements each provide that we will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer. We also maintain a general liability insurance policy, which will cover certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;16.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statements. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 7.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No.</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 91.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/ef20016457_ex4-1.htm">4.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of 12.0% Senior Convertible Notes (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/ef20016457_ex4-2.htm">4.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Warrant (incorporated by reference to Exhibit&#160;4.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/ef20016457_ex10-1.htm">10.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Securities Purchase Agreement, dated as of December&#160;14, 2023, by and among Eterna Therapeutics Inc. and the purchasers party thereto (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/ef20016457_ex10-2.htm">10.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration Rights Agreement, dated as of December&#160;14, 2023, by and among Eterna Therapeutics Inc. and the purchasers party thereto (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Current Report on Form&#160;8-K, filed on December&#160;20, 2023). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20018157x1_ex5-1.htm">5.1*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20018157x1_ex23-1.htm">23.1*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of the Independent Registered Accounting Firm, Grant Thornton LLP. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20018157x1_ex23-2.htm">23.2*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of the Independent Registered Accounting Firm, Marcum LLP. </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20018157x1_ex5-1.htm">23.3*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (Included in Exhibit&#160;5.1). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPOA">24.1*</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on the signature pages hereto). </div></td></tr><tr><td style="width: 7.69%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20018157x1_ex107.htm">107</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 91.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 50pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item&#160;17.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The undersigned registrant hereby undertakes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">i.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">iii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_301-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">provided<font style="font-style: normal;">, </font>however<font style="font-style: normal;">, that paragraphs (1)(i), (ii) and (iii) above do not apply if the information required to be </font><font style="font-style: normal;">included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished </font><font style="font-style: normal;">to the SEC by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 </font><font style="font-style: normal;">that are incorporated by reference in the registration statement or is contained in a form of prospectus filed </font><font style="font-style: normal;">pursuant to Rule&#160;424(b) that is part of the registration statement. </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining any liability under the Securities Act, each such post- effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(A)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each prospectus filed by the registrant pursuant to Rule&#160;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(B)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each prospectus required to be filed pursuant to Rule&#160;424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule&#160;430B relating to an offering being made pursuant to Rule&#160;415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule&#160;430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">i.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">iii.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">iv.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_301-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">report pursuant to Section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Insofar as indemnification for liabilities arising under the Securities may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="ny20018157x1_s3_302-signature_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSIG"><!--Anchor--></a>SIGNATURES </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#160;S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 12th day of January, 2024. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="7" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">ETERNA THERAPEUTICS INC.<font style="font-weight: normal;"> </font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.63%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 39.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Sanjeev Luther </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.63%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 39.96%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sanjeev Luther </div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.63%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 39.96%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Principal Executive Officer)</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;"><a name="tPOA"><!--Anchor--></a>POWER OF ATTORNEY </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Sanjeev Luther and Sandra Gurrola, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and any registration statement relating to the offering covered by this registration statement and filed pursuant to Rule&#160;462(b) under the Securities Act of 1933, as amended, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 26.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 41.03%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 26.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Sanjeev Luther</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Principal Executive Officer)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">January&#160;12, 2024 </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Sanjeev Luther</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Sandra Gurrola</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Senior Vice President of Finance<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Principal Financial and Accounting Officer)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">January&#160;12, 2024 </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Sandra Gurrola </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ James Bristol</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">January&#160;12, 2024 </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">James Bristol </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ William Wexler</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">January&#160;12, 2024 </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">William Wexler </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Dorothy J. Clarke</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 41.03%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td rowspan="2" style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">January&#160;12, 2024 </div></td></tr><tr><td style="width: 26.92%; text-align: center; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Dorothy J. Clarke</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; text-align: center;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 27-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ny20018157x1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 5.1</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z34e980e68f794b27b47a9e60f9ea862f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 73.3%; vertical-align: bottom;">
            <div style="text-align: center; text-indent: 180pt;"><img src="ny20018157x1_ex5-1img01.jpg" height="105" border="0" width="86"></div>
          </td>
          <td style="width: 26.54%; vertical-align: top;">
            <div style="text-align: right;">919 Third Avenue,</div>
            <div style="text-align: right;">New York, NY 10022</div>
            <div style="text-align: right;">212 935 3000</div>
            <div style="text-align: right;">mintz.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>January 12, 2024</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Eterna Therapeutics Inc.</div>
    <div style="text-align: justify;">1035 Cambridge Street, Suite 18A</div>
    <div style="text-align: justify;">Cambridge, MA 02141</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">We have acted as counsel to Eterna Therapeutics Inc. (the &#8220;Company&#8221;) in connection with the filing by the Company of a Registration Statement on Form S-3 (as amended, the &#8220;Registration Statement&#8221;)
      with the Securities and Exchange Commission (the &#8220;Commission&#8221;) relating to the registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of the offering from time to time by the selling stockholders, as described in the
      Registration Statement, of up to 18,233,359 shares of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;Common Stock&#8221;), including (i) 4,789,507 shares of Common Stock (the &#8220;Note Shares&#8221;) that are issuable upon conversion of the Company&#8217;s
      12% Senior Convertible Notes (the &#8220;Notes&#8221;), (ii) 3,864,838 shares of common stock that may become issuable upon conversion of capitalized pay-in-kind interest that may accrue through the maturity date of the Notes (the &#8220;PIK Interest Conversion
      Shares&#8221; and together with the Note Conversion Shares, the &#8220;Conversion Shares&#8221;), and (iii) 9,579,014 shares of Common Stock (the &#8220;Warrant Shares&#8221;) issuable upon the exercise of warrants to purchase shares of Common Stock (the &#8220;Warrants&#8221;). The Notes
      and Warrants were issued to certain accredited investors pursuant to a Securities Purchase Agreement dated December 14, 2023.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">In connection with this opinion, we have examined the Company&#8217;s Restated Articles of Incorporation and Second Amended and Restated Bylaws, each as currently in effect, such other records of the
      corporate proceedings of the Company and certificates of the Company&#8217;s officers as we have deemed relevant, and the Registration Statement and the exhibits thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to
      original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such copies, and the truth and correctness of any representations and warranties contained therein. As to questions of
      fact material to this opinion, we have relied upon certificates or comparable documents of public officials and of officers and representatives of the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">Our opinion is limited to the general corporate laws of the State of New York and we express no opinion with respect to the laws of any other jurisdiction. No opinion is expressed herein with
      respect to the qualification of the Conversion Shares and Warrant Shares under the securities or blue sky laws of any state or any foreign jurisdiction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">Based upon the foregoing and subject to the qualifications and assumptions stated herein, we are of the following opinion:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Conversion Shares, when delivered in accordance with the terms of the Notes, will be validly issued, fully paid and non-assessable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Warrant Shares, when delivered and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and non-assessable.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="text-align: justify;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>
      <div style="text-align: center; font-size: 8pt;">BOSTON&#160;&#160;&#160;&#160;&#160;&#160;LOS ANGELES&#160;&#160;&#160;&#160;&#160;&#160;NEW YORK&#160;&#160;&#160;&#160;&#160;&#160;SAN DIEGO&#160;&#160;&#160;&#160;&#160;&#160;SAN FRANCISCO&#160;&#160;&#160;&#160;&#160;&#160;TORONTO&#160;&#160;&#160;&#160;&#160;&#160; WASHINGTON</div>
    </div>
    <div style="font-size: 6pt;">
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.</div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="font-weight: bold;">
      <table id="z33fa9d5a7c2749739fa55fc7a124c1e1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;">
              <div style="text-align: left; font-weight: bold;">MINTZ</div>
              <div style="text-align: left; font-weight: bold;"> <br>
              </div>
              <div style="text-align: left;">January 12, 2024</div>
              <div style="text-align: left;">Page <font class="BRPFPageNumber">2</font></div>
            </td>
            <td style="width: 50%; text-align: right; vertical-align: middle;">
              <div>
                <div><img src="ny20018157x1_ex5-1img01.jpg" height="54" width="43"></div>
              </div>
            </td>
          </tr>

      </table>
      <br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes,
      rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 24.5pt;">We understand that you wish to file this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated
      under the Securities Act and to reference the firm&#8217;s name under the caption &#8220;Legal Matters&#8221; in the prospectus which forms part of the Registration Statement, and we hereby consent thereto. In giving this consent, we do not admit that we are within
      the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.</div>
    <div><br>
    </div>
    <div>Very truly yours,</div>
    <div><br>
    </div>
    <div>/s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</div>
    <div><br>
    </div>
    <div>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ny20018157x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 23.1<br>
    </div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div>We have issued our report dated March 20, 2023 with respect to the consolidated financial statements of Eterna Therapeutics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2022, which are incorporated by reference
      in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and to the use of our name as it appears under the caption &#8220;Experts.&#8221;</div>
    <div><br>
    </div>
    <div>/s/ Grant Thornton LLP<br>
    </div>
    <div><br>
    </div>
    <div>New York, New York</div>
    <div>January 12, 2024</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ny20018157x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-weight: bold;">Exhibit 23.2</font><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center;"><u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">We consent to the incorporation by reference in this Registration Statement of Eterna Therapeutics Inc. (formerly known as Brooklyn ImmunoTherapeutics,
      Inc.) on Form S-3 of our report dated April 15, 2022, except for Note 3, Restatement of Previously Reported Information and Note 15, Income Taxes, as to which the date is June 30, 2022, which includes an explanatory paragraph as to the Company&#8217;s
      ability to continue as a going concern, with respect to our audit of the consolidated financial statements of Eterna Therapeutics Inc. (formerly known as Brooklyn ImmunoTherapeutics, Inc.)<font style="font-weight: bold;">&#160;</font>as of December 31, 2021 and for the year ended December 31, 2021, appearing in the Annual Report on Form 10-K of Eterna Therapeutics Inc. (formerly known as Brooklyn ImmunoTherapeutics, Inc.)<font style="font-weight: bold;">&#160;</font>for the year ended December 31, 2022. We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in the Prospectus, which is part of
      this Registration Statement.</div>
    <div><br>
    </div>
    <div>/s/ Marcum <font style="font-variant: small-caps;">llp</font></div>
    <div><br>
    </div>
    <div>Marcum <font style="font-variant: small-caps;">llp</font></div>
    <div>New York, NY</div>
    <div>January 12, 2024</div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ny20018157x1_ex107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 107</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Calculation of Filing Fee Tables</div>
    <div style="text-align: center; font-weight: bold;">Form S-3</div>
    <div style="text-align: center;">(Form Type)</div>
    <div style="text-align: center; font-weight: bold;">Eterna Therapeutics Inc.</div>
    <div style="text-align: center;">(Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center;"><u>Table 1 - Newly Registered Securities</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z137ae4bb72ff46f383ecec815455cf5a" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10.63%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Security</div>
            <div style="text-align: center; font-weight: bold;">Type</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.83%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-weight: bold;">Security</div>
            <div style="text-align: center; font-weight: bold;">Class</div>
            <div style="text-align: center; font-weight: bold;">Title</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Fee</div>
            <div style="text-align: center; font-weight: bold;">Calculation</div>
            <div style="text-align: center; font-weight: bold;">or Carry</div>
            <div style="text-align: center; font-weight: bold;">Forward</div>
            <div style="text-align: center; font-weight: bold;">Rule</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Amount</div>
            <div style="text-align: center; font-weight: bold;">Registered(1)</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Proposed</div>
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Offering</div>
            <div style="text-align: center; font-weight: bold;">Price Per</div>
            <div style="text-align: center; font-weight: bold;">Unit(2)</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Maximum</div>
            <div style="text-align: center; font-weight: bold;">Aggregate</div>
            <div style="text-align: center; font-weight: bold;">Offering</div>
            <div style="text-align: center; font-weight: bold;">Price(2)</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Fee Rate</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Amount of</div>
            <div style="text-align: center; font-weight: bold;">Registration</div>
            <div style="text-align: center; font-weight: bold;">Fee</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom; background-color: #CCEEFF;">
            <div>Fees to Be Paid</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div>Equity</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 12.83%; vertical-align: bottom; background-color: #CCEEFF;">
            <div>Common stock, par value $0.005 per share</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 12%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Rule 457(c)</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">18,233,359 (3)</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
            <div>$</div>
          </td>
          <td style="width: 7.69%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">1.915</div>
          </td>
          <td style="width: 0.11%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
            <div>$</div>
          </td>
          <td style="width: 12.29%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">34,916,882.50</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
            <div>$</div>
          </td>
          <td style="width: 5.61%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">0.00014760</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">$</div>
          </td>
          <td style="width: 9.8%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">5,153.73</div>
          </td>
          <td style="width: 0.09%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom;">
            <div>Fees Previously Paid</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 8%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.83%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 7.69%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.11%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.29%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9.8%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.09%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td colspan="5" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Total Offering Amounts</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 7.69%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.11%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">
            <div>$</div>
          </td>
          <td style="width: 12.29%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">34,916,882.50</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">$</div>
          </td>
          <td style="width: 9.8%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">5,153.73</div>
          </td>
          <td style="width: 0.09%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="5" style="vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Total Fees Previously Paid</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 7.69%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.11%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.29%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 9.8%; vertical-align: bottom;">
            <div style="text-align: right;">-</div>
          </td>
          <td style="width: 0.09%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td colspan="5" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Total Fee Offsets</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 7.69%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.11%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 12.29%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td colspan="2" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 9.8%; vertical-align: bottom; background-color: #CCEEFF;">
            <div style="text-align: right;">-</div>
          </td>
          <td style="width: 0.09%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10.63%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td colspan="5" style="vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">Net Fee Due</div>
          </td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.24%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 7.69%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.11%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">&#160;</td>
          <td style="width: 12.29%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 0%; vertical-align: bottom;">&#160;</td>
          <td colspan="2" style="vertical-align: bottom;">&#160;</td>
          <td style="width: 0.06%; vertical-align: bottom;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom;">
            <div style="text-align: right;">$</div>
          </td>
          <td style="width: 9.8%; vertical-align: bottom;">
            <div style="text-align: right;">5,153.73</div>
          </td>
          <td style="width: 0.09%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0dbbe7d78ea04fb4b8910a55c4323e1a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">(1)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement shall also cover any additional shares of common stock, par value $0.005 per share (&#8220;common stock&#8221;), of
              Eterna Therapeutics Inc. (the &#8220;Company&#8221;) that may be offered or become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an
              increase in the number of outstanding shares of common stock.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z199eab9af64343f2913c45bdbdcd6d58" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">(2)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(c) under the Securities Act and based upon the average of the high and low sales prices of a share of common stock as reported on the Nasdaq
              Capital Market on January 10, 2024.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf83e2b2e48844738874df0c051dacb2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top;">(3)</td>
          <td style="width: auto; vertical-align: top;">
            <div>Representing 18,233,359&#160; shares of common stock, composed of (i) up to 4,789,507 shares of common stock issuable upon the conversion of the Company&#8217;s 12% Senior Convertible Notes (the &#8220;Notes&#8221;) that were issued by the Company in a private
              placement consummated in December 2023 (the &#8220;Private Placement&#8221;), (ii) up to 3,864,838 shares of common stock that may become issuable upon conversion of capitalized pay-in-kind interest that may accrue through the maturity date of the Notes,
              and (iii) up to 9,579,014 shares of common stock issuable upon the exercise of warrants issued by the Company in the Private Placement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ny20018157x1_ex5-1img01.jpg
<TEXT>
begin 644 ny20018157x1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0K!V(# 2(  A$! Q$!_\0
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M3/(V&[UQTCL6ZT 3W<HD<D54HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!:*2B@ HHHH *6DI: "E7K24J]: +D%7DZ51@J\G2@
M!]%%% '2/TK%O^];3]*Q;_O0!SUQ]^H:FN/OU#0 4E+24 )2TE+0 E%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 N:-U 6EVT )11B@4 &*<!29HS0 [ I":
M3-)C- "[J U)BC% $@Q4JOLZ56&:7)H TK?4)(W&#7H7A/6#OCW-7ER@YS6W
MIFH_96!W8Q0!]4^'=6A:%<N.E=2EW%(!M8&OFG1?&'ELJ^8?SKU+PYX@%UM^
M?/XT >E+@]*D%5K.021*?:K= "T4E+0 4AI:* &$4!:?2$XH 3%!I-XI,YH
M7-.%-Q3L4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 444AH 3BCBF'-)S0!+1313L4 -)--)-248%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4M)2T )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %*!24H- #MM)C!I=]+G- &OH]^MI*&;M7J_AOX@6MD$5F''
MO7B.*DA=@XPQH ^M])^(-I>!55AS[UV-EJ*7:!E[U\O>#[C$D>Y_UKW[PU=Q
M>0N9!T]: .RHJ))XV PP-29!H *;FEQ28H ,THIN*<* %I:** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 3BCBEI,4 )FE!I,4A95ZF@!DTXB4D]JP-0\406@(8BKFK7*);M\
MPKQCQAJI0OM;]: -OQ'XWMI490P_.O&O$>L"Z=BK=369J6L2/*PW'K6+-<&3
MJ: &22EF/-,S2=31B@!:2EQ1B@!M%+BC% "4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: "E7K24J]: +
MD%7DZ51@J\G2@!]%%% '2/TK%O\ O6T_2L6_[T <]<??J&IKC[]0T %)2TE
M"4M)2T )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %**2B@!V*.E)F@T +NHW4@I0* #-/1RAS28HH UK/69+8C
M!-=MX>\4S-*JEC^=>99YK<T2[2"8%CCF@#Z<\+:F;A$R>M=[$P9!S7@WA?Q9
M:6RH&D Q[UZ;IGBRTN54+*#GWH Z[8* ,5!:W:7"Y4YJWB@!H-.HQ2T %%)F
MDW"@!U%)N%+0 449I,T +12;A1F@!:*** "BDS1N% "T4F:6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T
M+129I: "BBB@ HHHH ***3- "T4FX49H 6BBHY)5C&2: 'G@5S^M:DUI&Q'8
M58N_$%I; [W KA?$OBRQDC95D&<>M '-^(O'L]J74,>/>O-M7\;37I8$GFF>
M*-2CN)'*-G-<3(^6- $]Y=M<.6/>J5/I.* $ IX44VC)H <5 IE+DFC% !FE
MS2C%+Q0 F:0TAI*  TE%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4M)2T %*O6DI5ZT 7(*O)TJC!5Y.E #Z***
M.D?I6+?]ZVGZ5BW_ 'H YZX^_4-37'WZAH *2EI* $I:2EH 2BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *7%)2
MB@!=M!6ER:3F@!.E/#4S!HH >6IA-%+B@!M.#LO0T8I,4 6[:\G5QB0C\:]*
M\'WTQ>/=(?SKRQ/E;-=%I&M/9,I!Z4 ?5OAN<- N6[>M=4KJ1UKYMT/X@3Q%
M4W'\Z]/T#Q5+>A<MUH ]%S1FJUI,98P3WJ>@ /--VFG4Z@!JK3J,TW- #J;B
MDW&E#4 )M-+C%.!HH 3-+F@BFT *>:3;0*<* $ IU%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4A%.HH B+8I
MOG8-2,H-,\H9H <LF:?FF! *?B@!I:@-S05%-/% $E-(J/><TX$F@ Z4;\4_
M;FHY1M7- #O,'K69JLP6W8AJR=8UDV:L0>E>=:YXZD4,F_\ 6@"KXPU.2,OM
MD/YUY!J6L3-*P,AZ^M;>O>(GO"V6SGWKA[F0NY/O0 ^:Y:0\DFJYYIM2*!0
MW%&*F"C%-(% $9%)3C3:  &G9IH%.Q0 F:2E--H =2444 )1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+24M !
M2KUI*5>M %R"KR=*HP5>3I0 ^BBB@#I'Z5BW_>MI^E8M_P!Z .>N/OU#4UQ]
M^H: "DI:2@!*6DI: $HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+=: .\S2;Z;&0R=:4QT /!S2XI@7%/!H 3;28I]!% #<TH-)BC% #J,4E**
M#%+249H 6BDS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %)2T4 ,.:;S3R:3=0 #-+0#2DT -YII%.+TW.: #
MIPI,4I&!0 I<"JEU<*L9YJAJNIBS0DGI7F^N_$%+3<N>E $WC&^PDFUJ\*U_
M4)3<-\QKH]<\=+>[@#UK@-0O/M,A;UH KO<NYY-1DYJ.E%  :,FEQ2[: $W&
MDW&EVT;: $R:*7%+0 VES0:;0 M%)2@T / I"* U(6H 0TE%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4M)2T %*
MO6DI5ZT 7(*O)TJC!5Y.E #Z*** .D?I6+?]ZVGZ5BW_ 'H YZX^_4-37'WZ
MAH *2EI* $I:2EH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** %S2YIM.% !1FER*;0 NZDS110 9HS124
M +2@XIM** '[S2;SFDXHH W-%NO)F!)[UZYX:\3+ $!D _&O"4E9#D&K]IJE
MS&XVN: /K/2O$J3A0) <^]=7:7(F3(-?-OA#5+B1X]SG\Z]X\.RL\"Y/:@#I
M":9DU*!Q1M% # 33\TN*0D"@!12XIF\4H84 +BEHI*  TVG44 (*=24M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "&FDT^DQ0 VC H(IO- #J*0&G9H ;MI0HHI: &NX09)K.NM5@A!W2 ?C2ZI
M(4@8@]J\<\7ZS<P%]DA'XT =1XFUVV>)@)5Z>M>&>*;Q)9'VOG\:S-3\0WDD
MC RMU]:P9[N6<Y9B<T 02'+GFF8H(.:* #%)3@12Y% #<T;J#24 +NHS24M
M"44O%% "4M)24 .Q1BDS2YH 0TE+10 E%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4M)2T %*O6DI5ZT 7(*O)T
MJC!5Y.E #Z*** .D?I6+?]ZVGZ5BW_>@#GKC[]0U-<??J&@ I*6DH 2EI*6@
M!**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 )FDW4IJ,YH =G-&*8#BGAQZT
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M HHHH *7;1FE#4 &*EBDV,"*CS24 ;UCK4MN1MD(_&NY\/>)[AY%4S-^=>4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*(;T+M;K[T =GP:0@5%!*)4!'>I:   4ZFTM "T4@I: "BBB@ HHHH ****
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MR>,=-GD>3:AKRN\TNX20Y0T 9>:7-.>%D/(IM "[J:33^*:: &T444 %%%%
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M- #*,T&EQ0 VEQ2XHS0 F*2ES10 E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M+B@4Z@!E%*:;0 \$
M4A--I0* $-%.VT8H !4@7-1YQ3@] "E:=% 96P*;\S=!6MI%JTDZ@J: )K'P
MY-<D%0:]"\,^$[B%U)4]?2MSPEH2RJFY:]7TWP_''&IVB@"GH5B]O  1VJMK
MO"-77?91#'P.U<EK_P!UJ /+==)RU>=ZN>6KT37>K5YWJ_5J .8D/S&F@TLO
MWC4= $G6DVT@.*7=0 X<4$TS=1UH ":;3L4$4 -HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M:2EH *5>M)2KUH N05>3I5&"KR=* 'T444 =(_2L6_[UM/TK%O\ O0!SUQ]^
MH:FN/OU#0 4E+24 )2TE+0 E%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4M)2T %*O6DI5ZT 7(*O)TJC!5Y.E #Z*** .D?I6+?]
MZVGZ5BW_ 'H YZX^_4-37'WZAH *2EI* $I:2EH 2BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% '2/TK%O^];3]*Q;_O0!SUQ]^H:FN/OU#0 4E+24 )2TE+0 E%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M48- !3:7%)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4M %."F@!!3MN:3&*L6L#2
MR #O0!$D3%N!77^&M/,LJ[E[U+I'A:>[*E4SGVKT?P]X*N8&5C&?RH Z3POX
M=ADC0E1T]*] M-%A@48 JEH>FO:HH88P*Z+!"T )'&L:X%25%AJ>H- "TM+1
MF@!,9HVBC-% "@4M)2T 0S_</TKB/$'W6KMY_N'Z5Q'B#[K4 >5Z[]YJ\\U?
MJU>AZ[]YJ\\U?JU ',2_>-,I\OWC3* "DI:2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "EI*6@ I5ZTE*O6@"Y!5Y.E48*O)TH ?1110!TC]*Q;_ +UM/TK%
MO^] '/7'WZAJ:X^_4- !24M)0 E+24M "4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5=T_P#UR_6J57=/_P!<OUH ]G\$=8Z]TT?_ (]E^E>%^".L=>Z:
M/_Q[+]* ->BBB@ HHHH *2EHH :3BF[Z<13,"@ W9I<9H IX% $,J+L/%>>^
M,(<QR86O1V (Q65?Z-%>@AQG- 'R9XHMY//;"'K7'O&ZL<J:^L-8^'UC,K,4
M'Y5Y1XG\(VUCO**./:@#R+FDJ_?P+#,RCL:J "@!HIP-! IIH ":;110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 +FE#4VB@"4/2%Z9BEQ0 $Y
MI,TN*,<T -YJQ;JWF#BK-C:>>X&,UVFD>%C<%3Y9.?:@#3\&*WF1\5] >'/^
M/=?I7G/ASPP;<H?+(Q[5ZII-MY$0&,4 :^>*3=1VI.* 'YHI!2\4 9FJ_P#'
MNWTKQ'QLKDOC->[W<8DC(KA]<\-I=[LIG\* /EG4HY//;@]:S"&'6O;M=\%1
M1[F\O]*\TUG2UM68 8Q0!S6:*>PPV*3 H  U&^D(I,&@!VZDW4F#28H ?NXI
M-U-%/ % "9IM2X%,- #:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6+?]ZVGZ5BW_>@#GKC[]0U-<??J&@ I*6DH 2EI*6@!**** "BBB@ HHHH
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M4BCU->N>'?!*SJC8H S?!^DNK)N6O;=$LT2W7*BLG3/"@LPI Z5U%K%Y"!:
M+8C5>@IPI <T[% !FEHQ1B@ Q3<4^DH ;@T4ZDQ0 <4N!28I<T +129HS0!%
M/]P_2N(\0?=:NWG^X:X;Q"WRM0!Y;KOWFKSS5^K5Z!KK_,U>>ZL>6H YJ7[Q
MIE/E^\:CS0 M)11B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!J0,*"PH CI:0TG- #L4FV@5("* (^11N-2'%1F@!<YHIN:6@ -)FEVYHVT
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M 'T444 =(_2L6_[UM/TK%O\ O0!SUQ]^H:FN/OU#0 4E+24 )2TE+0 E%%%
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MT>6:>K@=:D,JXH K\BDR:>S TR@!**** "BBB@ HHHH **** "BBB@ HHHH
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M.E %\\U6ELHYOO"K'![TO2@#EM8T"V:%CL'2O&/&&D1Q%]JU]#7D)FB*CO7
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M*5>M %R"KR=*HP5>3I0 ^BBB@#I'Z5BW_>MI^E8M_P!Z .>N/OU#4UQ]^H:
M"DI:2@!*6DI: $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J[I_\ KE^M
M4JNZ?_KE^M 'L_@CK'7NFC_\>Z_2O"_!'6.O=-'_ ./=?I0!K4444 )2TE+0
M M%%% !1110 4444 %%%% !1110 4444 %%%(:  FF[J1LTSF@!S\C%<]J^C
M+>JP(ZUT(([T$(U 'C&N?#V&;<Y7]*\RU[PE'8[L#I7U)J-LC0MQVKQWQEI[
M,'VK0!X#>0"*0J.U5:Z#5M.E$[':>M8[0,G44 1HF:G$*D5#G%)YI]: )&C
MJ$BG;B:3!H ;24XTV@ HHHH **** "BBB@ HHHH **** "BBB@!13@*93N:
M'8I**7B@!II*?MS2A* (^:7FIP%'6D;;0!#S3TB=B,*:FMXQ)*!CK7;:%X>^
MU%?W><T 9OANTD,ZY0]?2O>?"%B/+CROZ5BZ%X.\O:WE?I7I.C:7]E51MQB@
M#7@ME1!A15@,5X J9$^7%!510 T.:HW]Z;=":M27$<8.37)^(]2C6%L-VH R
M-9\9-;!ANZ>]>9^(?&+70<;NOO6;XMU5][[6KSJXOY7<Y8T 6=5O3<2DY[UD
M[SFE:0L>:;0 N\TA.: *> * &BG;J#BF$T /WTTO3:,4 +FE#8I*#0 [S*0L
M33:<,4  &:E6,4W(I-YH <T8%26\Q@D##M4.XFB@#M=&\8RV!4 GBO2-!^(\
M\Q5"Q_.O PQ!KJ?#=T$F7)[T ?4VA:V]\BDGK73H=RYKRKPEK$"1Q[G%>BVN
MJP2H-K"@#1VTC(-O04)*KC(-./2@#C_$\.Z!L)V]*\ \7V<QD?$9_*OI^^LU
MN%((S7&ZMX3M[@,3$#^% 'R=/:3*YRA'X5 4*]17M/B3PO!;!RL0&/:O*]6M
MQ#,0!B@#)I*** $HHI1B@ I0*?QBFDT  44[8*CR:-QH <5%,-+DFC!H ;12
MXI* "BBB@ HHHH **** "BBB@ HHHH ***6@ I<TE% "[JD@7>X%+#:R3'"B
MMFP\/W<K@K&>M '1>&_#T=\R!@.:]<T+X=VY17P*Y?PAH=U"R%D(KVW1(6CM
MU#"@"MIOAJ.Q V@<5T$:;%Q4G:F$T .XHXJ([J5=U $N*:13A29% "8IPI,B
ME% "T444 %%%% !1110 4444 %%%% !1110 VBBB@"*?[AKA?$7W6KNI_N&N
M%\1?=:@#RC7/O-7G^J]6KT#7/O-7G^J]6H YR3[QJ.I)/O&HZ "EI*6@!***
M* %HHHH 2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "EI*6@ I5ZTE*O6@"Y!5Y.E48*O)TH ?
M1110!TC]*Q;_ +UM/TK%O^] '/7'WZAJ:X^_4- !24M)0 E+24M "4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5=T_P#UR_6J57=/_P!<OUH ]G\$=8Z]
MTT?_ (]U^E>%^".L=>Z:/_Q[K]* -:BBB@!*6DI: %HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 2FD9IU)0!$4)H6,BIJ,T 5YH2Z$>M<IK'AIKP-A>M
M=GFD(XZ4 >#Z]X#=%9]GZ5Y9KVBM9LV1TKZG\0Q;K=L+VKP;QC83,\FV,_E0
M!Y'*-K8J.M&[L)T<Y0C\*HM&R]10  T[<*BI: %)IM.I* $HHHH **** "BB
MB@ HHHH **** "BBB@!13@:8*<!0 [K1MHHW&@!P.*4R#%19-)C- #]V3Q5N
MWLGG(QGFJT,99QQ7>>%])6Y=-PH H:3X<E>53M/Y5[!X2T/RMFY/TK8\/>$(
M&B5BH_*NXLM!BM0-H% %G3[2-(5^0=/2M (J]!38X]@Q3STH 7-5;R<11L?2
MF7%XD(.6 KF]7UV%8F'F#IZT 8_B#Q2MENRW2O,-<\>I*63=^M/\7ZHDV_;)
MG\:\EU"0M.QSWH U-6U@7C,0>M<\YRV:3)I,T %+FDHH =FC--HH =UI=M-S
M2[J %Z49IN:2@!<TE%% !113@* $I:7 I* %HS12X% "=ZOV5W]G8'-4>E-R
M: .^TGQ7]G*C?T]Z].\->*?M!0;^OO7SO"Y#]:[OPUJGV=TRV,>] 'U)I%T)
MH0<UL C%>2:!XK58U7S!^==UI^LK<@?,#GWH Z' -130JR'BG1-N4&GD9% '
MGOB70C=*^U>M>/:]X&F,C.%/Y5],S6:RCD5SVL:)&T+':.E 'R??^'Y+,G(/
M%8<J[&(KV3QAI7EE]JUY-?VSK*WRGK0!GDTE.*$=13: #-+FDIP% !UI=M+@
M4F<4 +C%&:;NI* %)IM+BC% "4444 %%%% !113L4 -HIV*3% "45(%HVB@"
M.BG$4V@ IR@[A3XHR[8 K9LM'DG(PA/X4 7O#MH)I5R.]>U>&/#T<J(3&/RK
MAO#7AZ:.128CU]*]M\,V9AC3*XXH T;#0T@4$(!^%;L,(C7 %2)@+3LB@!"*
M3;2YI,T .Q1Q12&@!"U-(S1BE% "!#3P**=0 4444 %%%% !1110 4444 %%
M%% !1110 VBEI* (I_N&N%\1?=:NZG^X:X7Q%]UJ /*-=^\U>?ZKU:N_UT_,
MU<!JO4T <Y)]XU'4DGWC4= !2T4M #:*6DH 6BDHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *6DI: "E7K24J]: +D%7DZ51@J\G2@!]%%% '2/TK%O^];3]*Q;_O0!SUQ
M]^H:FN/OU#0 4E+24 )2TE+0 E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %7=/_UR_6J57=/_ -<OUH ]G\$=8Z]TT?\ X]U^E>%^".L=>Z:/_P >Z_2@
M#6HHHH 2EI*6@!:*** "BBB@ HHHH **** "BBB@ HHHH ***0T !(II84C4
MV@!>:49I5IU  *#32U-+4 5KNW69"",UR6J^&8;@,3$#GVKM>M-D160\4 >!
M>)/"T, <B(#\*\DUJT6"4@#'-?3WBG3_ #D?"UXAXC\.R-*Q"GK0!YGWHXK6
MN])> G(-9;H4.* &TE+BC% #:*** "BBB@ HHHH **** "BBB@ HHHH *7)H
M IX2@! :?D4TIBF\T ..*LVMJT[ **JJC$]#73>';9GG7*=Z +>F>%[FX92L
M9/X5Z9X8\+W-NR%HR/PK>\(Z6C)&3&/RKTFTTZ.-!A /PH @T2U:"$ CM6Z"
M *A10@P!3SR* '[A3)FPAQ6?>WHM4+&N/U;QW'9A@2.* #Q7J$L"/M;%>(>(
MO$MXLK*)3U]:Z/Q'X\CO X!'->5ZO?BZE+"@".[UB>X)W.368[ESDTTGFDH
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M =Z^C/%FC37&_:I->.ZQX7NEE9MA_*@#B *0U?N]/EMR=PZ5G-D&@!#2444
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MU:N^UW[S5P.J=30!SLGWC4=22?>-,H 2EHI* "BBB@!:2EHH 2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "EI*6@ I5ZTE*O6@"Y!5Y.E48*O)TH ?1110!TC]*Q;_O6T_2L6
M_P"] '/7'WZAJ:X^_4- !24M)0 E+24M "4444 %%%% !1110 4444 %%%%
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M/Q']UJ /)]=^\U<#JG4UWNNGYFK@=4ZF@#GI/O&F4^3[QIE !24M)0 444M
M!1244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !12T4 )1110 4M)2T %*O6DI5ZT 7(*O)TJC!5Y.E #Z*
M** .D?I6+?\ >MI^E8M_WH YZX^_4-37'WZAH *2EI* $I:2EH 2BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "KNG_ .N7ZU2J[I_^N7ZT >S^".L=>Z:/
M_P >Z_2O"_!'6.O=-'_X]U^E &M1110 E+24M "T444 %%%% !1110 4444
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MB5MHH SO".CO"$W+7JME J1+QVJA8Z.ML!@5LHNU<4 +P*4&DQ2@4 .HHHH
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MO% "@T[(J/!IP!H ?12"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH 2@44"@"&X^X:X/Q']UJ[RX^X:X/Q']UJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %+24M !2KUI*5>M %R"KR=*HP5>3I0 ^B
MBB@#I'Z5BW_>MI^E8M_WH YZX^_4-37'WZAH *2EI* $I:2EH 2BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRCI3Z3% #0:=1BEH 0BF[*?10 S91MI]% #*7-+BC% "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-
MQ]PUP'B3[K5W]Q]PUY_XD^ZU 'DFN_?:N$U+J:[O7?OM7!ZEU- &!)]ZF4^3
M[U,H *6BEH ;12TE !12TE !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 44M% "4444 %+24M !2KUI*5>M
M%R"KR=*HP5>3I0 ^BBB@#I'Z5BW_ 'K:?I6+?]Z .>N/OU#4UQ]^H: "DI:2
M@!*6DI: $HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J[I_P#KE^M4JNZ?
M_KE^M 'L_@CK'7NFC_\ 'NOTKPOP1UCKW31_^/=?I0!K4444 )2TE+0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<OUJE5W3_P#7+]: /9_!'6.O=-'_ ./=?I7A?@CK'7NFC_\ 'NOTH UJ***
M$I:2EH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I#2TA- "8HZ4FZDZT /W"C-,Q1G% "FFD&G;J=Q0!'@
MTHS3^*:30 9IVX5&:,&@"K?H9(6 ]*\I\6>';N[W^6A.:]@V9ZTQ[6)Q\R _
MA0!\A:OX)U%)78Q-C/I7+W6D3VA(=2,5]=>)+"W$#$1+T]*\"\86ZK))M3'X
M4 >:;<'!IV!3I@0YXJ/-  13,5(*,4 1XI0*=FFYH =QBFFDI* %I*4"GA:
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MN \2_=>@#R37?OM7!ZEU-=WKOWVKA-2ZF@# D^]3*?)]ZF4 %+24M "4444
M+2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %+24M !2KUI*5>M %R"KR=*HP5>3I0 ^BB
MB@#I'Z5BW_>MI^E8M_WH YZX^_4-37'WZAH *2EI* $I:2EH 2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "KNG_ZY?K5*KNG_ .N7ZT >S^".L=>Z:/\
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M $%Q_JS]*X#Q+]UZ[^X_U9^E>?\ B7[KT >2:[]]JX34NIKN==^^U<+J/4T
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MJ,MFFTM !1BEHH 3%)2TE !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: "E7K24J]:
M+D%7DZ51@J\G2@!]%%% '2/TK%O^];3]*Q;_ +T <]<??J&IKC[]0T %)2TE
M "4M)2T )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5W3_P#7+]:I5=T_
M_7+]: /9_!'6.O=-'_X]U^E>%^".L=>Z:/\ \>Z_2@#6HHHH 2EI*6@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M +1110 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2TE+0 4J]:2E7K0!<@J\G2J,%7D
MZ4 /HHHH Z5^E8M_WK:?I6+?]#0!SMQ]^H14UQ]\U"* "DIV::: $I:2C% !
M112T )13J#0 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***<* &T4^DH ;5W3_P#7+]:I5=T__7+]
M: /9_!'6.O=-'_X]E^E>%^".L=>Z:/\ \>R_2@#6I*=2&@ HIN:4&@!U%)2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8I"@-.HH CV@49Q2F
MF[30 _.:IW=HLZX(JV!3N#0!P^J>%;>X#%D_2O,O$WA6"W5R$Z>U>_SQJR'B
MO._%NGF5'VB@#YHUJU6"9@!WK$QS7?\ B/0IC,Q"GKZ5Q\^FR0DY% %"EW4K
M*5.*;B@!=U+3<44 !IM+24 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX0T.[MRF^,C\*]BTN)HX%#"@#2S29I::: %Q2@5%DTX$T 24M,&:=0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !24&HB6H EI,U$"U2"@!<T4T
MYI,F@![#(K)O])%T"".M:PI<B@#S;6?!22(S;17DOB?PW]E+87I7TM>J'B85
MYOXDT)KK=A,Y]J /F6]MVCF88/6JF&':O6=1\$3O(Q$)Z^E8DW@>\!X@;\J
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M #Q7\J/[$L?^>*_E6EBC% &;_8EC_P \5_*C^Q+'_GBOY5I8HQ0!G?V)8_\
M/%?RI?[$LO\ GBOY5HTF: ,[^Q++_GBOY4AT2Q_YXK^5:6:3% &;_8=@?^6*
M?E0-!L!SY"?E6CBB@"K'I]M#]V-1^%6%VJ, 4N,T;* #.:*<%I<4 -XHR*7;
M2;: %R*7-)MI<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F!
M12$T !P*3>*0\TFR@!VX&EXIF,4!J )*:P- -.S0!7:(GK49LHW^\H-7*,4
M4#I5HW6)?RIIT6Q/6%?RK0(IN: *']B6/_/%?RH_L6Q_YXK^57\TN* ,_P#L
M6Q_YXK^5']B6/_/%?RK1Q2XH S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^
M>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E
M1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8E
MC_SQ7\JTL48H S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8EC_SQ
M7\JTL48H S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8EC_SQ7\JT
ML48H S?[$L?^>*_E1_8EC_SQ7\JTL48H S?[$L?^>*_E1_8=C_SQ7\JTL48H
M SUTBSCY6)1^%6$BBB^ZH%3D4TQT *&%.XJ+&*-] $M(:0-FG4 ,-**=BF$X
MH =2$5'O.:>&S0 N*<!129H "*;@T[-)0 H%.I!2T %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(:6B@")E--P14]-(H 9D=Z:T,<GWE!IY2DQB@"!M-
MMGZQK^51G1K-NL*_E5S=1OH H?V'8_\ /%?RI/[%L1_RQ7\JT-V:7&: ,[^Q
MK'_GBOY4?V+8_P#/%?RK1VT8H SO[%L?^>*_E1_8MC_SQ7\JT"*,4 4/[&L?
M^>*_E1_8MC_SQ7\JT *7% &=_8EC_P \5_*C^Q+'_GBOY5I8HQ0!F_V)8_\
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MBE%.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D-+10!'S2C-/Q10 E+110 4F*6B@!,4E.HH 2DIU% #
M.:49IV** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3%+
M10 PBF\U+28H 8!3MM.HH 9BBGT4 ,YI:=10 E)BG44 -Q2<T^C% #13J**
M"BBB@ HHHH **** "BBB@ HHHH *2EHH 2BEHH 2BEHH 2BEHH 2BEHH 2BE
MHH 2BEHH 2BEHH 813=O-2T8H 8!3J6B@ I",TM% #-@I=N*=10 VEQ2T4 )
MBC%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4E.HH
M9S1BGT4 -VT;13J* $VBBEHH 8<TG-248H 8*7%.HH 9S2C-.HH 04M%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "48I:* $I:** "BBB@ HHHH 0TVGT4 ,HI]% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4A;%%-(H -XIP;-0[:4'% $N:-U,W4N* %W4;Z3;2;:
M 'YI:9THS0 [-&:92B@!]%)2T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%(: #-&:3%% #J*2F%J ),TF:C#9
MIXYH 7-+3:,T .I,T9I.M !NI=U-VT8Q0 ^BF T[- "T444 %%%% !1110 4
M444 %%%% !1110 444F: %HII-)F@!])FC--)H =FDW4VEQ0 NZES2;:7% "
MYI,T&DH =13,TNZ@!U)FDS10 N:,TVB@!]%,W4F^@"2BF;J7- #J*3-% !FE
MS3:44 +129II:@!])FF[LTZ@ S1F@BDQ0 N:,T8I* '44S-)N- $E)FF;J.M
M #\TM,I<T .HI,TM !1110 4444 %%%% !1110 4444 %%%% !29I:0B@ W4
M9IN*,XH ?13<TN: %I,T48H 6BBB@ I,T9HH ,TM)BDS0 N:,TW-% #LTM,I
M<T +FC-%)B@!=U&:;BG4 +1110 444F: %I,TF:* '44E% !FEIM&: '44F:
M,T +29H--H =FC--I: '44E+0 44F:,T +129HS0 M%)FC- "T4F:,T +129
MHS0 M%)FC- "T4F:6@ HHHH **** "BBB@ HHHH **** "BBB@ I,T44 &:,
MTF*,4 .HI,TF: '44W-+F@!:3-%)0 N:7--HH =13<T9H =129HS0 M%)FC-
M "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129H
MS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F
M:,T +129HH 9S2YIV!3&% "Y%& :CVG-2**  BFDXI^*85H  32\TG2CS!0
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M-+FDI* '9%)28-&* %I:3%+0 TTWO4E)B@!!3J3%&* #BEXIFTTH% #J***
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M*GG3C\37?67BJQN5 653GWH W2M*%J*&ZCG7*G-2EJ '4TBC<*44 )2TM'%
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MD_.OD/\ X6!JO_/9OSH_X6!JO_/9OSH ^O/[9M?^>R?G1_;-K_SV3\Z^0_\
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M/9?I7@'@K[\=?0'AW_CV7Z4 =#CBC;3ATI: &A:-M.HH CVTFPU+10!&%-.
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M].@_U8KS#P;]R.O4+<_NQ0 \K1BG9I-U  ,TX4FZE!H 6BBB@ HHHH ****
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M0_%C6+*6<\>]>GZ'\4X454+#\Z /=L@4FX5Q.E>,X=1"X8<UU5M.DRA@PYH
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M4\%??CKZ \._\>R_2OG_ ,%??CKZ \._\>R_2@#HQTI:0=*6@ HHHH ****
M"BBB@ I**2@ S1FBB@!<T9I,TM "9I*=BC% #13A129H 6C-)FEH 2BEHQ0
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MD4A7- 6@"K??ZAOI7CGC;[LE>QWP_<M]*\<\;?=DH \+UG_CY;ZUC&MG6?\
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MT?:DI>U)0 HI:04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4C?=-+2-]TT <MXA_U3?2O%_$WWWKVCQ#_JF^E>+^)OOO0!YU
MJ'WC7/S_ 'JZ#4/O&N?G^]0!7HHHH L6G^M'UKUOP3]^.O)+3_6CZUZWX)^_
M'0![[H/_ ![+6^.E8&@_\>RUOCI0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %(<4M-- "$"FD&EIPH 8 :
M=FG4PT +FF\YIPI: &YI0:"M-QB@"2HG![4N_%.#9H K[6S4BCUJ4X[U%)(B
MC)84 2 BFR2!%R37/:KX@CL58[QQ7GNM?%);;<@- 'H&J>(8;,'<X&/>N!US
MQY:[602C/UKS37/B$U_N 8\UPE[J<MQ(6WGGWH [/Q!XD%TS;'Z^]</<74DC
MD[C5?S6/4DTF2: &LS'K3*L0PM*X&.M=5H_A)K\KQUH Y:WM7N&VJ#70Z?X-
MO;P@HA.?:O3-#^&!!5R*].T+PE'8JN4'% 'DOAWX>W<;(9(CCZ5ZWH7A6""-
M?,B&1[5V$-G%&H 0?E4X15Z"@"G!IEO"!M0"KBH%& *.E+F@!U%)FEH ****
M "BBB@ HHHH **** "BBB@#X"WFESFF44 28%(/O4W-"]: -_2#AUKTK0I2-
MM>:Z1]]:])T(?=H ]-T.0G;7=V1_="N#T,?=KN[/_5"@"]D4W(J-@:0 YH D
MI12"E(H 7(IK<C%)@THH SKS28KP$.HYKE-5^'UA<*S,@_*N^R*AG7>A% 'S
MKXG\$VMF',:#CVKRO4]/,$S!5Z5]3Z_H$EX&VKG->6ZYX$N06?R_TH \8\HC
MJ*0J*Z;5]"ELV;*D8]JYF12C8(H 5',;9%;5AXEN;$C8QX]ZP<TA- 'J6B_$
MF]1U1I"!]:]2T'QW'/&OG3#\37RZDK(<J:NQ:Q>0C"2L/QH ^H-;\7VPA8I.
MN<>M>1^(?&DV]A')D?6O/I-<OI!AIF/XU3DN9)3EF)H U;SQ!<7).YCS61+*
MTC9-1YJ1$+G H BQS4T5K++]Q2:N6^F22L,"NZ\,^'BTB;TS^% ''6/AZ]F=
M<0L1]*]*\,^"WE*^="1]17J/ASPS9^6I>%<X]*[2WT>U@4;(U'X4 <CH_@:T
MCC5B@S]*ZRST:&T V@<5HI&$& ,4Z@ 50HP*7%)FES0 8I:2EH ***6@"E?_
M .I;Z5XYXV^[)7LE_P#ZEOI7C?C;[LE 'A>L_P#'RWUK&-;.L_\ 'RWUK&-
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M!/'U%=1X>_X^%KEX^HKJ/#W_ !\+0![QX-^Y'7J%O_JQ7E_@W[D=>H6_^K%
M$M%%% #J*** "BBB@ HHHH **** "BBB@ HHHH *J7O^J;Z5;JI>_P"J;Z4
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ME_@W[D=>H6_^K% $M%%% #J*** "BBB@ HHHH **** "BBB@ HHHH *J7O\
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MAQS0!\[>(_ 4LC.8X\?05Y[J'@^YM"2RGCVKZYN],21#E17G/BG1 4?:GZ4
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M 'J$'^K%25'!_JQ4E "BB@44 )2TE+0 M)2TE "4M)2T %-IU-H 44ZFBG4
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M5'FI+?\ U@H ]4\%??CKZ \._P#'LM?/_@K[\=?0'AW_ (]EH Z/M24O:DH
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M0+0!(*"*04Z@!NVE I:* "BBDH ,T9I#28H =2TT4Z@ HHHH **** "BBB@
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M3\72WA8$GFN:N=0EN3EV)JH3F@"S<W!F<L35:BDH ,5+"@=P#46":>FY3D4
M=CHGAZWO"N]AS7H^C>!M/0*YD3\Z\8MM8N;3&QB,5J1^-]2B7 E;\Z /H_2K
M&QTY0!(G'O70+K5K$N!(G'O7RI_PGNJ?\]F_.FGQUJ9_Y;-^= 'U8?$EN.DJ
M_G2#Q+!_SU7\Z^43XWU(_P#+5OSH_P"$VU+_ )ZM^= 'UD/$=O\ \]5_.G#Q
M%;_\]5_.ODS_ (3C4_\ GJWYTO\ PG.I_P#/5OSH ^LO^$BM_P#GJOYTG_"1
MV_\ SU7\Z^3_ /A.=3_YZM^=)_PG&I_\]6_.@#ZP_P"$C@_YZK^='_"1V_\
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M:G_SU;\Z /K#_A([?_GJOYT?\)'!_P ]5_.OD_\ X3C4_P#GJWYT?\)QJ?\
MSU;\Z /K#_A(X/\ GJOYT?\ "1P?\]5_.OD__A.-3_YZM^='_"<:G_SU;\Z
M/K#_ (2.#_GJOYT?\)'!_P ]5_.OD_\ X3C4_P#GJWYT?\)QJ?\ SU;\Z /K
M#_A(X/\ GJOYT?\ "1P?\]5_.OD__A.-3_YZM^='_"<:G_SU;\Z /K#_ (2.
M#_GJOYT?\)'!_P ]5_.OD_\ X3C4_P#GJWYT?\)QJ?\ SU;\Z /K#_A(X/\
MGJOYT5\G_P#"<:G_ ,]6_.B@#E:*** %I1UI*4=: -[2/OK]:])T+^&O-M(^
M^OUKTG0OX: /3-"_AKO;'_5BN"T+^&N]L?\ 5B@"[2&EI#0 &B@T4 +1110
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MO4UEMUH ;2CK24HZT =-X;_X^%^M?07@O_5QU\^^&_\ CX7ZU]!>"_\ 5QT
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JBDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
